Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs specializes in premium anti-CDK4 antibodies, providing an extensive selection of rigorously tested products designed for superior performance. Our dedicated team provides expert customer support, ensuring your research goals are achieved with great efficacy and accuracy. Whether you're investigating cell cycle regulation, cancer biology, or drug discovery, our anti-CDK4 antibodies offer precision and reliability.
Cyclin-dependent kinase 4 (CDK4) is an essential cell cycle regulator, especially during the S phase transition. Its deregulation is commonly observed in various human tumors, such as breast cancer, gliomas, and melanomas, often through mechanisms like amplification or overexpression. Moreover, CDK4 has been identified as a prognostic marker, particularly in triple-negative breast cancer (TNBC). Owing to its noteworthy role in the advancement of cancer, CDK4 represents a very intriguing avenue for investigational cancer treatments.
Cyclin-dependent kinase 4; CMM3; cyclin dependent kinase 4; cell division protein kinase 4; PSK-J3; EC 2.7.11.22; EC 2.7.11.
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.
Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins
Intracellular
Low cell type specificity
Low immune cell specificity
Group enriched (HBEC3-KT, LHCN-M2, RH-30)
Component of the D-CDK4 complex, composed of CDK4 and some D-type G1 cyclin (CCND1, CCND2 or CCND3). Interacts directly in the complex with CCND1, CCND2 or CCND3. Interacts with SEI1 and ZNF655. Forms a ternary complex, cyclin D-CDK4-CDKN1B, involved in modulating CDK4 enzymatic activity. Interacts directly with CDKN1B (phosphorylated on 'Tyr-88' and 'Tyr-89'); the interaction allows assembly of the cyclin D-CDK4 complex, Thr-172 phosphorylation, nuclear translocation and enhances the cyclin D-CDK4 complex activity. CDK4 activity is either inhibited or enhanced depending on stoichiometry of complex. The non-tyrosine-phosphorylated form of CDKN1B prevents T-loop phosphorylation of CDK4 producing inactive CDK4. Interacts (unphosphorylated form) with CDK2. Also forms ternary complexes with CDKN1A or CDKN2A. Interacts directly with CDKN1A (via its N-terminal); the interaction promotes the assembly of the cyclin D-CDK4 complex, its nuclear translocation and promotes the cyclin D-dependent enzyme activity of CDK4. Interacts with CCND1; the interaction is prevented with the binding of CCND1 to INSM1 during cell cycle progression. Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 (PubMed:29127155). Interacts with CEBPA (when phosphorylated) (PubMed:15107404). Interacts with FNIP1 and FNIP2 (PubMed:27353360).
Kinase, Serine/threonine-protein kinase, Transferase
Creative Biolabs offers a comprehensive range of anti-CDK4 antibodies designed to specifically block CDK4 protein. We offer our products in multiple formats to accommodate a wide array of experimental methods, ensuring seamless integration into your research workflows. In addition, we are committed to providing high-quality antibodies at competitive prices to meet the specific needs of researchers.
Table 1. Featured anti-CDK4 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
VS3-FY348 | Recombinant Rabbit Anti-CDK4 Antibody (clone R07-4G7) | Human | Rabbit IgG | WB, IHC, IF |
VS-0423-CJ3 | Human Anti-CDK4 Recombinant Antibody (clone AK2) | Human | Human IgG | ELISA, IF |
VS3-FY346 | Recombinant Rabbit Anti-CDK4 Antibody (clone R04-4I5) | Human, Mouse, Rat | Rabbit IgG | WB, IHC-F, IHC-P, IHC, IF, IP |
ZG-0613J | Rabbit Anti-CDK4 Recombinant Antibody (clone 8H4) | Human | Rabbit IgG | ELISA, WB |
ZG-0404F | Mouse Anti-Cdk4 Recombinant Antibody (ZG-0404F) | Human, Mouse, Rat, Dog, Pig | Mouse IgG | WB |
Creative Biolabs is committed to empowering researchers with a diverse selection of high-quality anti-CDK4 antibodies. Each antibody undergoes stringent quality assurance processes to ensure exceptional performance in a variety of applications. Our dedication to excellence ensures that our products adhere to the highest standards in the industry, providing researchers with dependable and consistent results.
Fig.1 WB analysis of anti-CDK4 antibody
(Cat# VS3-FY346, Creative Biolabs).
Fig.2 IHC analysis of anti-CDK4 antibody
(Cat# VS3-FY346, Creative Biolabs)
Fig.3 WB analysis of anti-CDK4 antibody
(Cat# ZG-0613J, Creative Biolabs).
Fig.4 IP analysis of anti-CDK4 antibody
(Cat# ZG-0612J, Creative Biolabs)
Our advanced recombinant antibody platform leverages genetic engineering to produce high-performance anti-CDK4 antibodies. This cutting-edge system enables efficient and scalable manufacturing, ensuring a reliable supply for diverse applications.
Featured Anti-CDK4 Recombinant Antibody Production Platforms
Fig.5 Milligram-scale anti-CDK4 recombinant antibody production.
Fig.6 Gram-scale anti-CDK4 recombinant antibody production.
Creative Biolabs offers a wide range of high-quality anti-CDK4 recombinant antibodies in various formats to suit your specific research needs.
Fig.7 Full-length anti-CDK4 recombinant antibody production and modalities.
Table 2. Public drug targeting CDK4.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Launched - 2017 |
Aromatase (CYP19A1) Inhibitors Cyclin-Dependent Kinase 4 (CDK4) Inhibitors Cyclin-Dependent Kinase 6 (CDK6) Inhibitors Signal Transduction Modulators |
Cancer Hormone Therapy Multi-Component Products Radiosensitizers |
Cancer, breast | Novartis (Originator) |
Phase I/II |
Cyclin-Dependent Kinase 4 (CDK4) Inhibitors Signal Transduction Modulators |
Peptides |
Cancer, bladder Cancer, colorectal Digestive-gastrointestinal cancer Glioblastoma multiforme Melanoma |
MetaMax (Originator) |
IND Filed |
Cyclin-Dependent Kinase 4 (CDK4) Degradation Inducers Cyclin-Dependent Kinase 6 (CDK6) Degradation Inducers Drugs Targeting Protein Cereblon (CRBN) Signal Transduction Modulators |
PROTACs (Proteolysis Targeting Chimeras) |
Cancer, breast Cancer, solid tumor |
BioTheryX (Originator) |
Preclinical |
Cyclin-Dependent Kinase 4 (CDK4) Degradation Inducers Cyclin-Dependent Kinase 6 (CDK6) Degradation Inducers Drugs Targeting Von Hippel-Lindau Disease Tumor Suppressor (VHL) Signal Transduction Modulators |
Oligopeptides, less than 10 AA PROTACs (Proteolysis Targeting Chimeras) |
Cancer | Icahn School of Medicine at Mount Sinai (Originator) |
Biological Testing |
CDK4/Cyclin D3 Inhibitors CDK6/Cyclin D3 Inhibitors Cyclin-Dependent Kinase 4 (CDK4) Inhibitors Cyclin-Dependent Kinase 6 (CDK6) Inhibitors Drugs Targeting EGFR (HER1; erbB1) Signal Transduction Modulators |
Antibody-Drug Conjugates (ADCs) Cancer Immunotherapy Chimeric Monoclonal Antibodies |
Cancer | Yonsei University (Originator) |
Biological Testing |
Cyclin-Dependent Kinase 4 (CDK4) Degradation Inducers Cyclin-Dependent Kinase 6 (CDK6) Degradation Inducers Drugs Targeting Inhibitor of Apoptosis Proteins (IAP) Signal Transduction Modulators |
Oligopeptides, less than 10 AA PROTACs (Proteolysis Targeting Chimeras) SNIPERs (Specific and Nongenetic IAP-Dependent Protein Eraser) |
Cancer | GSK (Originator) |
Biological Testing |
Cyclin-Dependent Kinase 4 (CDK4) Degradation Inducers Cyclin-Dependent Kinase 6 (CDK6) Degradation Inducers Drugs Targeting Von Hippel-Lindau Disease Tumor Suppressor (VHL) Signal Transduction Modulators |
Oligopeptides, less than 10 AA PROTACs (Proteolysis Targeting Chimeras) |
Cancer | GSK (Originator) |
Biological Testing |
Cyclin-Dependent Kinase 4 (CDK4) Inhibitors Cyclin-Dependent Kinase 6 (CDK6) Inhibitors Signal Transduction Modulators |
Polypeptides, from 10 AA to 40 AA | Cancer | Cyclacel (Originator) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a pioneer in antibody research, Creative Biolabs combines a strong theoretical foundation with extensive practical experience to deliver affordable, high-quality anti-CDK4 antibodies. If you want to learn more about our anti-CDK4 antibody, please feel free to contact us.